Determinants of Drug-Induced Hepatotoxicity Among Patients with Human Immunodeficiency Virus Taking a High Dose of Rifapentine Plus Isoniazid Drugs at the All Africa Leprosy Tuberculosis Rehabilitation and Training Center in Addis Ababa, Ethiopia | Zendy

Leuel Lisanwork Arage | Zendy; Haji Aman Deybasso | Zendy; Delelegn Yilma Gebremichael | Zendy; Binyam Gintamo Nuramo | Zendy; Zelalem Negash Mekuria | Zendy

Open Access

Determinants of Drug-Induced Hepatotoxicity Among Patients with Human Immunodeficiency Virus Taking a High Dose of Rifapentine Plus Isoniazid Drugs at the All Africa Leprosy Tuberculosis Rehabilitation and Training Center in Addis Ababa, Ethiopia

Author(s) -

Leuel Lisanwork Arage,

Haji Aman Deybasso,

Delelegn Yilma Gebremichael,

Binyam Gintamo Nuramo,

Zelalem Negash Mekuria

Publication year - 2021

Publication title -

hiv/aids - research and palliative care

Language(s) - English

Resource type - Journals

ISSN - 1179-1373

DOI - 10.2147/hiv.s300135

Subject(s) - rifapentine , medicine , tuberculosis , leprosy , isoniazid , odds ratio , latent tuberculosis , confidence interval , immunology , mycobacterium tuberculosis , pathology

The drugs for the treatment of latent Tuberculosis are potentially hepatotoxic and can lead to drug-induced hepatotoxicity. The current study aimed at identifying the determinants of anti-tuberculosis drug-induced hepatotoxicity among patients living with Human Immunodeficiency Virus taking Isoniazid and rifapentine at All Africa Leprosy Tuberculosis Rehabilitation and Training Center in Addis Ababa, Ethiopia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research